In aging common marmosets (Callithrix jacchus), submandibular glands exhibit a striking degenerative profile: loss of mucous and serous acinar units, ductal and stromal expansion, elevated collagen deposition, dysregulated lipid metabolism, and increased apoptotic and senescent cell burdens. Chronic oral rapamycin — an mTOR inhibitor — partially reversed these changes, preserving acinar architecture, reducing fibrosis, clearing lipid accumulation, and lowering senescent cell counts, shifting tissue phenotype measurably toward a younger state.
Salivary gland aging is chronically underappreciated in longevity research, yet xerostomia affects roughly 30% of adults over 65, cascading into malnutrition, oral infection, and reduced quality of life. Most mechanistic work has relied on rodent models whose salivary gland anatomy diverges significantly from humans — making the marmoset's human-like SMG histology genuinely valuable here. Rapamycin's effect on senescent cell clearance and fibrosis reduction aligns with its established mTOR-mediated suppression of SASP (senescence-associated secretory phenotype), extending that narrative into a clinically relevant tissue.
Limitations are real: this is a non-human primate study without reported cohort sizes or quantitative effect magnitudes in the abstract, and causality between mTOR inhibition and specific cellular outcomes needs mechanistic dissection. Still, as a translational bridge between rodent data and eventual human trials, this is meaningfully incremental — positioning rapamycin as a candidate gerotherapeutic for oral tissue aging, not just systemic longevity endpoints.